AZN vs MNKD

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.

MannKind Corporation presents a high-risk profile characterized by a Piotroski F-Score of 4/9, indicating only stable financial health. There is a severe disconnect between the current market price of $2.74 and the growth-based intrinsic value of $0.14, suggesting the stock is trading at a massive premium. While revenue growth is impressive at 45.8%, the company suffers from negative shareholders' equity (P/B of -16.51) and consistent earnings misses. Bearish insider activity and a 0/100 technical trend further undermine the optimistic analyst target prices.